| First Author | Kim KB | Year | 2022 |
| Journal | Sci Adv | Volume | 8 |
| Issue | 7 | Pages | eabl4618 |
| PubMed ID | 35171684 | Mgi Jnum | J:321525 |
| Mgi Id | MGI:6887110 | Doi | 10.1126/sciadv.abl4618 |
| Citation | Kim KB, et al. (2022) KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer. Sci Adv 8(7):eabl4618 |
| abstractText | EP300, a transcription coactivator important in proliferation and differentiation, is frequently mutated in diverse cancer types, including small cell lung cancer (SCLC). While these mutations are thought to result in loss of EP300 function, the impact on tumorigenesis remains largely unknown. Here, we demonstrate that EP300 mutants lacking acetyltransferase domain accelerate tumor development in mouse models of SCLC. However, unexpectedly, complete Ep300 knockout suppresses SCLC development and proliferation. Dissection of EP300 domains identified kinase inducible domain-interacting (KIX) domain, specifically its interaction with transcription factors including MYB, as the determinant of protumorigenic activity. Ala(627) in EP300 KIX results in a higher protein-binding affinity than Asp(647) at the equivalent position in CREBBP KIX, underlying the selectivity of KIX-binding partners for EP300. Blockade of KIX-mediated interactions inhibits SCLC development in mice and cell growth. This study unravels domain-specific roles for EP300 in SCLC and unique vulnerability of the EP300 KIX domain for therapeutic intervention. |
